# Round 1 Review — Codex gpt-5.5 (xhigh)

threadId: 019ed797-431e-7f42-8a52-319b8966f395
Date: 2026-06-17

**Score: 5.5/10 (NeurIPS/ICML); ~4.5/10 (Nature Methods). Verdict: Not ready.**

## Raw response (verbatim)

Using the review-loop rubric, but only doing the Round 1 assessment you asked for.

**Score: 5.5 / 10 against NeurIPS / ICML methods-track standards.** Against **Nature Methods**, lower, around **4.5 / 10**, because the method needs stronger biomedical construct validity, external label authority, and clearer clinical/scientific utility.

**Verdict: Almost? No. Current state: Not ready.** The idea is valuable and timely, but the empirical foundation is still too internally defined. The strongest contribution is the governance framing; the weakest part is whether the benchmark actually proves claim-faithfulness rather than enforcing your own post hoc statistical preferences.

**Critical Weaknesses**

1. Ground truth is still the central liability. Proxy/split-half/synthetic stress labels are not enough for a top-venue claim about "false confirmed" findings. Reviewers will say the benchmark is circular: CONFIRM defines admissibility, then wins by applying those admissibility rules. Fix: freeze an external label table before running more claims, with documented literature provenance, direction, expected scale, confidence; add a blinded adjudication pass independent of CONFIRM gates.
2. FCR denominator too small. 0/7 with CI upper ≈0.41 is underpowered. Fix: expand to ~25-50 inadmissible/null/fragile claims; report exact binomial / beta-binomial intervals.
3. Baseline story vulnerable to straw-man criticism. Fix: make hierarchy explicit — exec_only is an ablation (execution-integrity validation), not a competitor; real comparison is CONFIRM vs NeuroClaw adaptation vs generic DS agent vs ablated CONFIRM. Don't overclaim against un-runnable systems.
4. Risks reading as a gate ladder, not a discovery system. Fix: frame the main method as claim-state governance for agentic science; native agent is a demonstration harness, the modular layer is the reusable contribution.
5. Replication criterion change defensible but needs formal justification. "Same sign + independent significance after ComBat" can admit heterogeneous effects with poor transportability. Fix: heterogeneity audit — cohort-specific standardized effects, sign, p, optional random-effects/meta summary; flag "replicated but heterogeneous."
6. Power gate and replication gate need clearer separation. Fix: predefine power/admissibility rules with simulations/analytic thresholds; show cases where replication passes but power/stability downgrades, and vice versa.
7. Claim labels can be gamed (abstain-all wins FCR). Fix: evaluate at fixed known-positive recall centrally; report coverage, abstention rate, KP recall, fragile-abstain rate, candidate-yield; admissibility ROC by relaxing/tightening thresholds.

**Planned Expansion Critique**

Label table necessary but not yet adequate. Add fields: label_class, label_basis, adjudication_status, expected_direction (with coding), expected_effect_scale (standardized β/range), minimum_detectable_effect_assumption, cohort_role, forbidden_evidence (anti-leakage), confound_set, site/scanner handling, decision_target, construct_validity_notes, label_confidence (ordinal + reason).

Aging atrophy and sex differences are good positive anchors (strong, boring, hard to miss) — but define the estimand (raw vs eTIV-adjusted regional volume vs cortical thickness vs global morphology); sex is prone to head-size/scanner/sampling confounds.

Autism and ADHD plausible but dangerous: ABIDE-II and ADHD-200 are multi-site, heterogeneous, motion-sensitive, diagnostically messy. A null/fragile result could reflect poor harmonization, phenotype mismatch, site leakage, or weak features rather than true fragility. Minimum defensible fragile definition: literature suggests weak/heterogeneous effects AND the claim fails predeclared multiverse/site/replication checks WHILE positive controls pass in the same pipeline. Don't label "false" — label "not admissibly confirmable under this derivative-table contract."

BWAS task is important and should move earlier — it tests the most interesting behavior: confirm small effects only when scale and replication make them admissible. Counters the "CONFIRM is just conservative" criticism.

NeuroClaw baseline should not wait too long. Without it, the work is mostly an ablation study plus governance story.

Schizophrenia deferral is fine; state explicitly the benchmark excludes claims where local derivative tables cannot instantiate the literature claim.

**Ready? No.** Solid workshop/methods preprint; with the expansion done rigorously, could become "almost."
